Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Vistagen (NASDAQ: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Tuesday, August 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 first quarter ended June 30, 2024 and provide a corporate update.

Event: Vistagen Fiscal Year 2025 First Quarter Corporate Update Conference Call
Date: Tuesday, August 13, 2024
Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)
US Dial-in (Toll-free): 1-877-407-9716
TOLL/International Dial-in: 1-201-493-6779
Conference ID: 13748020
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1680978&tp_key=f7af16cbaa

An audio webcast of the conference call will also be available via the link provided above. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time) on Tuesday, August 13, 2024. To listen to the replay, call toll-free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay access ID number 13748020.

About Vistagen

Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on its pioneering approach and deep understanding of nose-to-brain neurocircuitry. Designed exclusively as nasal sprays administered at microgram level doses, Vistagen’s diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact olfactory system and brain neurocircuitry. Favorable safety profiles have been observed in all clinical studies of Vistagen’s pherine product candidates completed to date. Vistagen’s neuroscience pipeline also includes an oral prodrug with the potential to modulate NMDA receptor activity in multiple neurological conditions, such as levodopa-induced dyskinesia associated with Parkinson’s disease therapy and neuropathic pain. At Vistagen, we are passionate about creating novel and differentiated treatments that set new standards of care for millions of people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806711001/en/